We are testing a new treatment called CLN-049 for patients with acute myeloid leukemia who have measurable residual disease. This study aims to find the right dose and assess its safety.
Health conditions and diseases that the clinical trial is designed to study and treat.
Acute Myeloid Leukemia (AML) is a fast-growing cancer of the blood and bone marrow that results in the overproduction of immature white blood cells, leading to symptoms such as fatigue, frequent infections, and easy bruising or bleeding.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
